Key points
- Semaglutide reduces C-reactive protein (CRP) by approximately 38% — a reduction comparable to dedicated anti-inflammatory therapies
- Anti-inflammatory effects occur through both weight-loss-dependent and direct pharmacological mechanisms
- GLP-1 receptor activation directly modulates immune cell behaviour, reducing pro-inflammatory cytokine production
- Chronic inflammation is a key driver of atherosclerosis, type 2 diabetes, fatty liver disease and certain cancers
- Clinical trials are investigating GLP-1 agonists in psoriasis, inflammatory bowel disease and other immune-mediated conditions
The link between obesity and chronic inflammation
Chronic low-grade inflammation is now recognised as one of the most important mechanisms through which obesity causes disease. Unlike the acute inflammation that follows an injury or infection (which is protective and self-limiting), chronic inflammation persists for months or years, silently damaging tissues throughout the body.
Adipose tissue — particularly visceral fat surrounding the abdominal organs — is not simply an inert energy store. It functions as an active endocrine organ, producing a range of signalling molecules called adipokines and cytokines. In obesity, the balance of these molecules shifts decisively towards a pro-inflammatory state.
Key inflammatory mediators in obesity
| Mediator | Role in inflammation | Effect of obesity |
|---|---|---|
| TNF-α (tumour necrosis factor alpha) | Promotes insulin resistance, activates inflammatory pathways | Increased |
| IL-6 (interleukin-6) | Drives CRP production in the liver, promotes systemic inflammation | Increased |
| CRP (C-reactive protein) | Marker of systemic inflammation; directly contributes to atherosclerosis | Increased |
| MCP-1 (monocyte chemoattractant protein-1) | Recruits immune cells into adipose tissue and arterial walls | Increased |
| Adiponectin | Anti-inflammatory, insulin-sensitising | Decreased |
| Leptin | Satiety signalling, but pro-inflammatory at high levels | Increased (with resistance) |
This chronic inflammatory state contributes to virtually every major complication of obesity: cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, certain cancers, and accelerated ageing.
How GLP-1 medications reduce inflammation
GLP-1 receptor agonists reduce chronic inflammation through multiple complementary pathways. Importantly, some of these effects are independent of weight loss, suggesting direct anti-inflammatory properties of the medication itself.
1. Weight-loss-mediated effects
Losing visceral fat reduces the volume of metabolically active adipose tissue producing pro-inflammatory cytokines. As patients lose weight on semaglutide or tirzepatide, the inflammatory burden of their adipose tissue decreases proportionally. Studies show that a 10 per cent reduction in body weight typically produces a 25–30 per cent reduction in CRP.
2. Direct effects on immune cells
GLP-1 receptors are expressed on multiple immune cell types, including monocytes, macrophages and T lymphocytes. Activation of these receptors shifts macrophage polarisation from the pro-inflammatory M1 phenotype towards the anti-inflammatory M2 phenotype. This reduces the production of TNF-α, IL-6 and other pro-inflammatory mediators.
Research has also shown that GLP-1 receptor agonists inhibit the NF-κB signalling pathway — a master regulator of inflammatory gene expression — in both immune cells and endothelial cells. This provides a molecular mechanism for the observed anti-inflammatory effects.
3. Hepatic anti-inflammatory effects
The liver plays a central role in systemic inflammation, producing CRP and other acute-phase proteins in response to IL-6 signalling. By reducing hepatic fat content and improving insulin sensitivity, GLP-1 agonists decrease hepatic inflammation and lower CRP production at its source. This is particularly relevant for patients with non-alcoholic fatty liver disease, where hepatic inflammation drives both liver damage and systemic inflammatory burden.
4. Endothelial protection
GLP-1 receptor agonists reduce endothelial inflammation — the inflammatory activation of blood vessel walls that initiates and propagates atherosclerosis. Preclinical studies show reduced expression of adhesion molecules (VCAM-1, ICAM-1) that recruit inflammatory cells into the arterial wall, and decreased production of reactive oxygen species by endothelial cells.
Key evidence: The SELECT trial measured high-sensitivity CRP as a prespecified secondary endpoint. Semaglutide reduced CRP by approximately 38 per cent compared with placebo, and this reduction correlated with cardiovascular benefit independently of the degree of weight loss. This suggests that the anti-inflammatory effect is a distinct therapeutic mechanism, not merely a consequence of losing weight.
Inflammation and cardiovascular disease
The connection between inflammation and heart disease has been established through decades of research. Atherosclerosis — the process of plaque formation in arterial walls — is fundamentally an inflammatory disease. Chronic inflammation promotes every stage of atherosclerosis: initiation (endothelial dysfunction), progression (foam cell and plaque formation), and the catastrophic complication of plaque rupture that causes heart attacks and strokes.
The landmark CANTOS trial (2017) demonstrated that reducing inflammation with canakinumab (an IL-1β inhibitor) reduced cardiovascular events independently of cholesterol lowering, establishing the inflammatory hypothesis of atherosclerosis in clinical practice. The SELECT trial results with semaglutide fit neatly into this framework: a medication that reduces both metabolic risk factors and inflammation produces significant cardiovascular protection.
Beyond cardiovascular disease: other inflammatory conditions
The anti-inflammatory properties of GLP-1 agonists have generated interest in their potential application to conditions where chronic inflammation plays a central role. While none of the following indications is currently approved, research is active and producing intriguing preliminary results.
Non-alcoholic steatohepatitis (NASH)
NASH is the inflammatory form of fatty liver disease, characterised by hepatic inflammation and progressive fibrosis. Semaglutide has shown significant benefit in reducing liver inflammation and fibrosis in the phase 2 trial programme, with phase 3 trials ongoing. Given that NASH has no approved pharmacological treatment in the UK, GLP-1 agonists represent one of the most promising therapeutic approaches.
Psoriasis
Psoriasis is an immune-mediated skin condition driven by TNF-α, IL-17 and IL-23. Obesity is a known risk factor for psoriasis, and weight loss improves disease severity. Case reports and small studies suggest that GLP-1 agonists may improve psoriasis symptoms beyond what would be expected from weight loss alone, possibly through direct immunomodulatory effects. Formal clinical trials are underway.
Inflammatory bowel disease
GLP-1 receptors are expressed in the gastrointestinal tract, and preclinical data suggest that GLP-1 receptor activation may reduce intestinal inflammation. Early clinical observations indicate potential benefit in Crohn's disease and ulcerative colitis, but this remains highly preliminary and GLP-1 medications should not be used off-label for IBD.
Rheumatoid arthritis
Given that GLP-1 agonists reduce systemic inflammatory mediators including TNF-α and IL-6 — the same targets as established rheumatoid arthritis biologics — there is theoretical interest in their potential joint benefits. However, clinical evidence is limited to case reports and observational studies.
Neurodegenerative diseases
Neuroinflammation is implicated in Alzheimer's disease and Parkinson's disease. GLP-1 receptors are present in the brain, and preclinical studies show neuroprotective and anti-inflammatory effects. Clinical trials of semaglutide and liraglutide in Alzheimer's disease are ongoing, with results expected from 2026 onwards. The mental health implications of GLP-1 therapy are an active area of investigation.
Important: GLP-1 medications are currently licensed only for type 2 diabetes and weight management (with additional cardiovascular indication for semaglutide). They should not be used off-label for autoimmune or inflammatory conditions without specialist guidance. The research described above is promising but preliminary.
Measuring inflammation: what your blood tests show
If you are taking a GLP-1 medication, your doctor may monitor inflammatory markers alongside standard metabolic tests. The most commonly measured marker is high-sensitivity CRP (hs-CRP).
| hs-CRP level | Interpretation | Cardiovascular risk |
|---|---|---|
| Below 1 mg/L | Low inflammation | Lower risk |
| 1–3 mg/L | Moderate inflammation | Average risk |
| Above 3 mg/L | High inflammation | Elevated risk |
| Above 10 mg/L | Acute inflammation (infection or acute illness) | Requires investigation |
A reduction in hs-CRP from, say, 5 mg/L to 3 mg/L while on semaglutide would represent a meaningful improvement in systemic inflammation and is consistent with the trial data. However, CRP is just one marker, and clinical decisions should be based on the overall picture rather than a single blood test.
Lifestyle factors that complement anti-inflammatory treatment
GLP-1 medications are most effective when combined with lifestyle modifications that themselves reduce inflammation.
- Anti-inflammatory diet: Mediterranean-style eating patterns rich in vegetables, fruits, wholegrains, oily fish and olive oil have robust evidence for reducing inflammatory markers
- Regular physical activity: Exercise produces anti-inflammatory myokines (muscle-derived signalling molecules) and reduces visceral fat independently of weight loss
- Adequate sleep: Poor sleep quality and sleep apnoea promote systemic inflammation; treating sleep disorders complements medication effects
- Stress management: Chronic psychological stress activates the hypothalamic-pituitary-adrenal axis, promoting cortisol-driven inflammation
- Smoking cessation: Smoking is one of the most potent drivers of vascular inflammation and dramatically increases cardiovascular risk
Practical takeaway: While GLP-1 medications provide a powerful pharmacological reduction in inflammation, combining them with an anti-inflammatory lifestyle maximises the benefit. A comprehensive approach — medication, diet, exercise and sleep optimisation — is more effective than any single intervention alone.
The future: GLP-1 agonists as anti-inflammatory therapies
The recognition that GLP-1 receptor agonists have significant anti-inflammatory properties is shifting how these medications are perceived. Originally developed as glucose-lowering agents for diabetes, then repurposed for weight management, they are now being investigated as potential treatments for a range of inflammatory and immune-mediated conditions.
The next generation of incretin-based therapies — including triple agonists targeting GLP-1, GIP and glucagon receptors — may have even greater anti-inflammatory effects. Early data from retatrutide trials show substantial reductions in liver fat and inflammatory markers, suggesting that the anti-inflammatory potential of this drug class has not yet been fully realised.
For patients in the United Kingdom, the practical implication is straightforward: if you are prescribed a GLP-1 medication for weight management or diabetes, you are likely receiving meaningful anti-inflammatory benefit as well — a bonus that contributes to the cardiovascular protection, liver health improvements and kidney benefits increasingly documented in clinical trials.